Human medicines European public assessment report (EPAR): Penbraya, Meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed), Date of authorisation: 14/11/2024, Status: Withdrawn

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) – September 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 September 2025, 10:00 (CEST) to 24 September 2025, 12:00 (CEST)

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) – April 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 29 April 2025, 10:00 (CEST) to 29 April 2025, 12:00 (CEST)

Questions and answers clinic on post-authorisation procedure management in IRIS - 17 Jan 2025, Online, from 17 January 2025, 10:00 (CET) to 17 January 2025, 11:00 (CET)

Human medicines European public assessment report (EPAR): Xiliarx, vildagliptin, Date of authorisation: 19/11/2008, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Krka d.d., emtricitabine,tenofovir disoproxil, Date of authorisation: 28/04/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Enyglid, repaglinide, Date of authorisation: 13/10/2009, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Nivestim, filgrastim, Date of authorisation: 07/06/2010, Revision: 31, Status: Authorised

Appendix 1: Acceptable intakes established for N-nitrosamines

Appendix 1: Acceptable intakes established for N-nitrosamines